Expression and targeting of interleukin-4 receptor for primary and advanced ovarian cancer therapy

Cancer Research

Volumn 65, Issue 18, 2005, Pages 8388-8396

  Kioi, Mitomu ^a   Takahashi, Satoru ^a   Kawakami, Mariko ^a   Kawakami, Koji ^a   Kreitman, Robert J ^a   Puri, Raj K ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIN; INTERLEUKIN 4 CYTOTOXIN; INTERLEUKIN 4 RECEPTOR; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; METASTASIS; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS; TUMOR VOLUME;

ANIMALS; CACHEXIA; CELL GROWTH PROCESSES; CELL LINE, TUMOR; EXOTOXINS; FEMALE; HUMANS; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; RECEPTORS, INTERLEUKIN-4; RECOMBINANT FUSION PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 24944576949     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1043     Document Type: Article

References (39)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Hensley ML. Epithelial ovarian cancer. Curr Treat Options Oncol 2002;3:131-41.
3. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950-5.
4. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:1001-7.
5. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 1999;17:701-38.
6. Toi M, Bicknell R, Harris AL. Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res 1992;52:275-9.
7. Topp MS, Papadimitriou CA, Eitelbach F, et al. Recombinant human interleukin 4 has antiproliferative activity on human tumor cell lines derived from epithelial and nonepithelial histologies. Cancer Res 1995;55:2173-6.
8. Stadler WM, Rybak ME, Vogelzang NJ. A phase II study of subcutaneous recombinant human interleukin-4 in metastatic renal cell carcinoma. Cancer 1995;76:1629-33.
9. Whitehead RP, Lew D, Flanigan RC, et al. Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a southwest oncology group study. J Immunother 2002;25:352-8.
10. Kawakami M, Kawakami K, Stepensky VA, et al. Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy. Clin Cancer Res 2002;8:3503-11.
11. Joshi BH, Leland P, Asher A, Prayson RA, Varricchio F, Puri RK. In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures. Cancer Res 2001;61:8058-61.
12. Leland P, Taguchi J, Husain SR, Kreitman RJ, Pastan I, Puri RK. Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo. Mol Med 2000;6:165-78.
13. Kawakami K, Kawakami M, Husain SR, Puri RK. Targeting interleukin-4 receptors for effective pancreatic cancer therapy. Cancer Res 2002;62:3575-80.
14. Puri RK, Leland P, Obiri NI, et al. An improved circularly permuted interleukin 4-toxin is highly cytotoxic to human renal cell carcinoma cells. Introduction of γ c chain in RCC cells does not improve sensitivity. Cell Immunol 1996;171:80-6.
15. Husain SR, Kreitman RJ, Pastan I, Puri RK. Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model. Nat Med 1999;5:817-22.
16. Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 2000;6:2157-65.
17. Weber F, Asher A, Bucholz R, et al. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 2003;64:125-37.
18. Garland L, Gitlitz B, Ebbinghaus S, et al. Phase I trial of intravenous IL-4 Pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor. J Immunother 2005;4:376-81.
19. Murata T, Obiri NI, Puri RK. Human ovarian-carcinoma cell lines express IL-4 and IL-13 receptors: comparison between IL-4- and IL-13-induced signal transduction. Int J Cancer 1997;70:230-40.
20. Rodriguez-Burford C, Barnes MN, Oelschlager DK, et al. Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res 2002;8:202-9.
21. Zeuthen J, Norgaard JO, Avner P, et al. Characterization of a human ovarian teratocarcinoma-derived cell line. Int J Cancer 1980;25:19-32.
22. Kreitman RJ, Puri RK, Pastan I. A circularly permuted recombinant interleukin 4 toxin with increased activity. Proc Natl Acad Sci U S A 1994;91:6889-93.
23. Murata T, Obiri NI, Debinski W, Puri RK. Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem Biophys Res Commun 1997;238:90-4.
24. Kioi M, Kawakami K, Puri HK. Mechanism of action of interleukin-13 antagonist (IL-13E13K) in cells expressing various types of IL-4R. Cell Immunol 2004;229:41-51.
25. Noguchi M, Stamey TA, McNeal JE, Yemoto CE. Assessment of morphometric measurements of prostate carcinoma volume. Cancer 2000;89:1056-64.
26. Zurawski SM, Chomarat P, Djossou O, et al. The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor. J Biol Chem 1995;270:13869-78.
27. Edmondson RJ, Monaghan JM. The epidemiology of ovarian cancer. Int J Gynecol Cancer 2001;11:423-9.
28. Kawakami K, Kawakami M, Puri RK. Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy. Crit Rev Immunol 2001;21:299-310.
29. Kreitman RJ, Puri RK, Pastan I. Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma. Cancer Res 1995;55:3357-63.
30. Puri RK, Hoon DS, Leland P, et al. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res 1996;56:5631-7.
31. Ghadersohi A, Chitta K, Greco WR, et al. Tumor antigens and markers for breast and ovarian cancers. Front Biosci 2002;7:e48-57.
32. Shahin MS, Hughes JH, Sood AK, Buller RE. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 2000;89:2006-17.
33. Miyamoto S, Hirata M, Yamazaki A, et al. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res 2004;64:5720-7.
34. Abu-Jawdeh GM, Faix JD, Niloff J, et al. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 1996;74:1105-15.
35. Meden H, Marx D, Raab T, Kron M, Schauer A, Kuhn W. EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value. J Obstet Gynaecol 1995;21:167-78.
36. Hussain MM, Kotz H, Minasian L, et al. Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer. J Clin Oncol 2003;21:4356-63.
37. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003;21:283-90.
38. Alper O, Bergmann-Leitner ES, Bennett TA, Hacker NF, Stromberg K, Stetler-Stevenson WG. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst 2001;93:1375-84.
39. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002;20:1-13S.